Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Ravaioli

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Expert Opinion on Therapeutic Targets|August 13, 2022
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancerMichela Cortesi, Michele Zanoni, Roberta Maltoni, et al.
Histopathology|June 27, 2018
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer?Maurizio Puccetti, Sara Ravaioli, Maria M Tumedei, et al.
International Journal of Experimental Pathology|December 2, 2017
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapySara Ravaioli, Maria Maddalena Tumedei, Flavia Foca, et al.
International Journal of Molecular Sciences|January 11, 2022
Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the SpotlightMichela Cortesi, Michele Zanoni, Francesca Pirini, et al.
International Journal of Environmental Research and Public Health|April 3, 2021
Expanding Roles of De Novo Lipogenesis in Breast CancerPasquale Simeone, Stefano Tacconi, Serena Longo, et al.
Clinical Breast Cancer|March 24, 2020
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2<sup>+</sup> Early-stage Breast Cancer?Roberta Maltoni, Michela Palleschi, Mattia Altini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-LetterSara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, et al.
Scientific Reports|May 8, 2021
Spotlight on PSMA as a new theranostic biomarker for bladder cancerMaria Maddalena Tumedei, Sara Ravaioli, Federica Matteucci, et al.
Translational Oncology|December 5, 2021
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, et al.
Frontiers in Endocrinology|September 16, 2022
Androgen receptor in breast cancer: The "5W" questionsSara Ravaioli, Roberta Maltoni, Barbara Pasculli, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Expert Opinion on Therapeutic Targets|August 13, 2022
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancerMichela Cortesi, Michele Zanoni, Roberta Maltoni, et al.
Histopathology|June 27, 2018
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer?Maurizio Puccetti, Sara Ravaioli, Maria M Tumedei, et al.
International Journal of Experimental Pathology|December 2, 2017
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapySara Ravaioli, Maria Maddalena Tumedei, Flavia Foca, et al.
International Journal of Molecular Sciences|January 11, 2022
Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the SpotlightMichela Cortesi, Michele Zanoni, Francesca Pirini, et al.
International Journal of Environmental Research and Public Health|April 3, 2021
Expanding Roles of De Novo Lipogenesis in Breast CancerPasquale Simeone, Stefano Tacconi, Serena Longo, et al.
Clinical Breast Cancer|March 24, 2020
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2<sup>+</sup> Early-stage Breast Cancer?Roberta Maltoni, Michela Palleschi, Mattia Altini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-LetterSara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, et al.
Scientific Reports|May 8, 2021
Spotlight on PSMA as a new theranostic biomarker for bladder cancerMaria Maddalena Tumedei, Sara Ravaioli, Federica Matteucci, et al.
Translational Oncology|December 5, 2021
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, et al.
Frontiers in Endocrinology|September 16, 2022
Androgen receptor in breast cancer: The "5W" questionsSara Ravaioli, Roberta Maltoni, Barbara Pasculli, et al.
Pageof 6